[HTML][HTML] Current and novel antiplatelet therapies for the treatment of cardiovascular diseases
G Jourdi, M Lordkipanidze, A Philippe… - International journal of …, 2021 - mdpi.com
Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
G Jourdi, M Lordkipanidzé… - International …, 2021 - pubmed.ncbi.nlm.nih.gov
Over the last decades, antiplatelet agents, mainly aspirin and P2Y 12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
Current and novel antiplatelet therapies for the treatment of cardiovascular diseases
G Jourdi, M Lordkipanidzé… - International …, 2021 - papyrus.bib.umontreal.ca
Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
[PDF][PDF] Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
G Jourdi, M Lordkipanidzé, A Philippe… - Int. J. Mol. Sci, 2021 - academia.edu
Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
[HTML][HTML] Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
G Jourdi, M Lordkipanidzé, A Philippe… - … Journal of Molecular …, 2021 - ncbi.nlm.nih.gov
Over the last decades, antiplatelet agents, mainly aspirin and P2Y 12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases.
G Jourdi, M Lordkipanidzé, A Philippe… - International …, 2021 - search.ebscohost.com
Over the last decades, antiplatelet agents, mainly aspirin and P2Y< sub> 12 receptor
antagonists, have significantly reduced morbidity and mortality associated with arterial …
antagonists, have significantly reduced morbidity and mortality associated with arterial …
Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
G Jourdi, M Lordkipanidzé, A Philippe… - 2021 - agris.fao.org
Over the last decades, antiplatelet agents, mainly aspirin and P2Y< sub> 12</sub> receptor
antagonists, have significantly reduced morbidity and mortality associated with arterial …
antagonists, have significantly reduced morbidity and mortality associated with arterial …
Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
G Jourdi, M Lordkipanidzé, A Philippe… - International …, 2021 - search.proquest.com
Over the last decades, antiplatelet agents, mainly aspirin and P2Y 12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases.
G Jourdi, M Lordkipanidzé, A Philippe… - … Journal of Molecular …, 2021 - europepmc.org
Over the last decades, antiplatelet agents, mainly aspirin and P2Y 12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …